- In vivo antitumoral efficacy of PhAc-ALGP-doxorubicin, an enzyme-activated doxorubicin prodrug, in patient-derived soft tissue sarcoma xenograft models(2017)
Authors: Jasmien Cornillie, Agnieszka Wozniak, Peter Pokreisz, Andrea Casazza, Yemarshet Kelemework Gebreyohannes, Maria Debiec-Rychter, Raf Sciot, Daphne Hompes, Patrick Schöffski
Pages: 1566 - 1575
- Volatile organic compounds in gastrointestinal stromal tumour tissue originating from patient-derived xenografts(2017)
Authors: Agnieszka Wozniak, Yemarshet Kelemework Gebreyohannes, Patrick Schöffski
Pages: 037101
- A precision therapy against cancers driven by KIT/PDGFRA mutations(2017)
Authors: Agnieszka Wozniak, Yemarshet Kelemework Gebreyohannes, Patrick Schöffski
- Cabozantinib is active against human gastrointestinal stromal tumor xenografts carrying different KIT mutations(2016)
Authors: Yemarshet Kelemework Gebreyohannes, Patrick Schöffski, Jasmien Cornillie, Maria Debiec-Rychter, Raf Sciot, Agnieszka Wozniak
Pages: 2845 - 2852
- Characterization and assessment of the sensitivity and resistance of a newly established human gastrointestinal stromal tumour xenograft model to treatment with tyrosine kinase inhibitors(2014)
Authors: Thomas Van Looy, Yemarshet Kelemework Gebreyohannes, Agnieszka Wozniak, Jasmien Cornillie, Haifu Li, Beppe Floris, Maria Debiec-Rychter, Raf Sciot, Patrick Schöffski
Pages: 10